Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

364 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. Richardson PG, et al. Among authors: orlowski rz. N Engl J Med. 2003 Jun 26;348(26):2609-17. doi: 10.1056/NEJMoa030288. N Engl J Med. 2003. PMID: 12826635 Free article. Clinical Trial.
Proteasome inhibitors in cancer therapy.
Orlowski RZ. Orlowski RZ. Methods Mol Biol. 2005;301:339-50. doi: 10.1385/1-59259-895-1:339. Methods Mol Biol. 2005. PMID: 15917644 Review.
Proteasome inhibitors in the treatment of multiple myeloma.
Shah JJ, Orlowski RZ. Shah JJ, et al. Among authors: orlowski rz. Leukemia. 2009 Nov;23(11):1964-79. doi: 10.1038/leu.2009.173. Epub 2009 Sep 10. Leukemia. 2009. PMID: 19741722 Free PMC article. Review.
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS. Vij R, et al. Among authors: orlowski rz. Blood. 2012 Jun 14;119(24):5661-70. doi: 10.1182/blood-2012-03-414359. Epub 2012 May 3. Blood. 2012. PMID: 22555973 Free PMC article. Clinical Trial.
Proteasome inhibitors in multiple myeloma: 10 years later.
Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL. Moreau P, et al. Among authors: orlowski rz. Blood. 2012 Aug 2;120(5):947-59. doi: 10.1182/blood-2012-04-403733. Epub 2012 May 29. Blood. 2012. PMID: 22645181 Free PMC article. Review.
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS. Jagannath S, et al. Among authors: orlowski rz. Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):310-8. doi: 10.1016/j.clml.2012.08.003. Clin Lymphoma Myeloma Leuk. 2012. PMID: 23040437 Clinical Trial.
Future agents and treatment directions in multiple myeloma.
Ocio EM, Mitsiades CS, Orlowski RZ, Anderson KC. Ocio EM, et al. Among authors: orlowski rz. Expert Rev Hematol. 2014 Feb;7(1):127-41. doi: 10.1586/17474086.2014.858595. Epub 2013 Dec 18. Expert Rev Hematol. 2014. PMID: 24350987 Free PMC article. Review.
The proteasome as a target for cancer therapy.
Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. Voorhees PM, et al. Among authors: orlowski rz. Clin Cancer Res. 2003 Dec 15;9(17):6316-25. Clin Cancer Res. 2003. PMID: 14695130 Review.
364 results